TICKERNERD
Menu
TVTXTVTXHealthcare · Biotechnology

TVTX Stock Forecast: Travere Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$55
−1.63% on the day

The 15 Wall Street analysts covering Travere Therapeutics, Inc. hold a median 12-month price target of $61 — +10.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$5.2B
Ticker Nerd rank
94 / 100
Median analyst target
$61
Analysts covering
15
Total return, dividends reinvested
1W
−3.0%
1M
−3.4%
YTD
+43.9%
1Y
+251.8%
From 52W high
−6.9%
From 52W low
+244.5%
$16
$59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TVTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Travere Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Momentum
95
Value
94
Growth
92
Accruals
84
Issuance
77
Volatility
38
Revisions
30
Size
24

Quality (99): The business earns solid, repeatable profits on what it owns.

Revisions (30): Analysts have, on balance, been cutting their forecasts.

Size (24): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Travere Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

TVTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TVTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26TVTXHigh $70Median $61Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
14 Buy1 Hold0 Sell
Low $43Median $61High $70

The green dot is the last close — the median target sits +10.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 July 2026Canaccord GenuityMaintainsBuy$56 → $62
25 June 2026GuggenheimMaintainsBuy—
25 June 2026GuggenheimMaintainsBuy$56 → $65
22 June 2026WedbushMaintainsOutperform—
22 June 2026WedbushMaintainsOutperform$55 → $61
18 June 2026Evercore ISI GroupMaintainsOutperform—
18 June 2026Evercore ISI GroupMaintainsOutperform$52 → $60
15 June 2026CitigroupMaintainsBuy—
12 June 2026Wells FargoMaintainsOverweight—
3 June 2026CitigroupMaintainsBuy—
3 June 2026WedbushReiteratesOutperform—
2 June 2026HC Wainwright & Co.MaintainsBuy—
6 May 2026Wells FargoMaintainsOverweight—
5 May 2026CitigroupMaintainsBuy—
5 May 2026HC Wainwright & Co.MaintainsBuy—
5 May 2026TD CowenMaintainsBuy—
5 May 2026WedbushMaintainsOutperform—
24 Apr 2026GuggenheimMaintainsBuy—
14 Apr 2026Canaccord GenuityMaintainsBuy—
14 Apr 2026CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

TVTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+17.0%
Analysts raising
2
Analysts cutting
2
Fundamentals

Travere Therapeutics, Inc. (TVTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−186.6×

Cheaper than 99% of US stocks

Price / sales
9.4×

Cheaper than 15% of US stocks

Price / book
50.6×

Cheaper than 2% of US stocks

EV / EBITDA
327.0×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
55.6%

Higher than 88% of US stocks

Earnings growth (YoY)
55.6%

Higher than 79% of US stocks

Gross margin
79.0%

Higher than 90% of US stocks

Operating margin
−29.0%

Higher than 21% of US stocks

Net margin
−4.0%

Higher than 25% of US stocks

Returns & dividend
Return on equity
−69.4%

Higher than 17% of US stocks

Return on assets
−6.5%

Higher than 30% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TVTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TVTXTravere Therapeutics, Inc.$5.2B
94
DYNDyne Therapeutics, Inc.$4.6B
27
CRSPCRISPR Therapeutics AG$4.6B
19
SRRKScholar Rock Holding Corp.$5.4B
28
PTCTPTC Therapeutics, Inc.$5.6B
70
DFTXDefinium Therapeutics, Inc.$5.6B
38
CAICaris Life Sciences, Inc.$4.4B
30
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TVTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest TVTX news & analysis

Travere Therapeutics to Report Second Quarter 2026 Financial Results

Business Wire · 28 July 2026neutral

Travere Therapeutics announced it will report its second quarter 2026 financial results after market close on August 4, 2026, and will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update.

Why it matters — Investors and analysts will gain insight into the company's recent financial performance and receive a general business update directly from management.

FAQ

Frequently asked questions about TVTX stock

What is the TVTX stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Travere Therapeutics, Inc. have a median 12-month price target of $61, with estimates ranging from $43 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TVTX stock a buy right now?

Of the 15 analysts covering Travere Therapeutics, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Travere Therapeutics, Inc. 94 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TVTX?

As at 1 Aug 2026, Travere Therapeutics, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will TVTX stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +10.0% from the last close, and Ticker Nerd's factor model ranks Travere Therapeutics, Inc. 94 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TVTX stock forecast for 2030?

No analyst covering Travere Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TVTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $70 over the next 12 months.

How has TVTX stock performed over the past year?

Travere Therapeutics, Inc. returned +251.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Travere Therapeutics, Inc. do?

Travere Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of pioneering therapies for rare diseases.

What is the latest news on TVTX?

The most recent item we track (Business Wire, 28 July 2026): "Travere Therapeutics to Report Second Quarter 2026 Financial Results". Travere Therapeutics announced it will report its second quarter 2026 financial results after market close on August 4, 2026, and will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update.

Company

About Travere Therapeutics, Inc.

Travere Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of pioneering therapies for rare diseases. The company's primary mission is to address unmet medical needs in patient populations that have few existing treatment options. Travere Therapeutics operates in the pharmaceutical sector, focusing predominantly on nephrology and hepatology. Its pipeline includes drug candidates aimed at treating complex conditions like focal segmental glomerulosclerosis (FSGS) and Alport syndrome, both of which are linked to kidney diseases. With a strong commitment to advancing scientific research and improving patient outcomes, Travere Therapeutics partners with healthcare professionals and scientists to drive innovation in niche medical areas. The company plays a significant role in the biotech industry, providing new avenues for treating challenging health issues that affect small populations. Travere's presence in the rare disease market underscores its significance as a leader in providing hope and solutions for patients who desperately need breakthrough therapeutics.

CEO Dr. Eric M. Dube Ph.D. · 497 employees · United States · https://travere.com